Access to Glucagon

Ken discusses the high coverage rates for commercially insured individuals for the new glucagon product, with 87% of plans in the U.S. offering unrestricted coverage. He highlights the copay assistance program, ensuring affordability with a zero-dollar out-of-pocket cost for the hypopen, making it more accessible to those in need.